XML 17 R7.htm IDEA: XBRL DOCUMENT
v3.23.2

REVENUE | 6 Months Ended
--- | ---
Jun. 30, 2023
Revenue from Contract with Customer [Abstract] |
Revenue | REVENUE The following table summarizes the disaggregation of revenue by nature:
| Three Months Ended June 30, |  | Six Months Ended June 30,
Dollars in millions | 2023 |  | 2022 |  | 2023 |  | 2022
Net product sales | $ | 10,917 |  |  | $ | 11,485 |  |  | $ | 21,965 |  |  | $ | 22,793 |
Alliance revenues | 179 |  |  | 199 |  |  | 323 |  |  | 387 |
Other revenues | 130 |  |  | 203 |  |  | 275 |  |  | 355 |
Total Revenues | $ | 11,226 |  |  | $ | 11,887 |  |  | $ | 22,563 |  |  | $ | 23,535 |
The following table summarizes GTN adjustments:
| Three Months Ended June 30, |  | Six Months Ended June 30,
Dollars in millions | 2023 |  | 2022 |  | 2023 |  | 2022
Gross product sales | $ | 18,111 |  |  | $ | 17,299 |  |  | $ | 35,399 |  |  | $ | 33,949 |
GTN adjustments (a) |  |  |  |  |  |  |
Charge-backs and cash discounts | (2,279) |  |  | (1,750) |  |  | (4,370) |  |  | (3,513) |
Medicaid and Medicare rebates | (3,143) |  |  | (2,624) |  |  | (5,625) |  |  | (4,708) |
Other rebates, returns, discounts and adjustments | (1,772) |  |  | (1,440) |  |  | (3,439) |  |  | (2,935) |
Total GTN adjustments | (7,194) |  |  | (5,814) |  |  | (13,434) |  |  | (11,156) |
Net product sales | $ | 10,917 |  |  | $ | 11,485 |  |  | $ | 21,965 |  |  | $ | 22,793 |
(a) Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $11 million and $98 million for the three and six months ended June 30, 2023 and $123 million and $197 million for the three and six months ended June 30, 2022, respectively. The following table summarizes the disaggregation of revenue by product and region:
| Three Months Ended June 30, |  | Six Months Ended June 30,
Dollars in millions | 2023 |  | 2022 |  | 2023 |  | 2022
In-Line Products |  |  |  |  |  |  |
Eliquis | $ | 3,204 |  |  | $ | 3,235 |  |  | 6,627 |  |  | 6,446 |
Opdivo | 2,145 |  |  | 2,063 |  |  | 4,347 |  |  | 3,986 |
Pomalyst/Imnovid | 847 |  |  | 908 |  |  | 1,679 |  |  | 1,734 |
Orencia | 927 |  |  | 876 |  |  | 1,691 |  |  | 1,668 |
Sprycel | 458 |  |  | 544 |  |  | 887 |  |  | 1,027 |
Yervoy | 585 |  |  | 525 |  |  | 1,093 |  |  | 1,040 |
Mature and other products | 472 |  |  | 512 |  |  | 939 |  |  | 1,049 |
Total In-Line Products | 8,638 |  |  | 8,663 |  |  | 17,263 |  |  | 16,950 |
New Product Portfolio |  |  |  |  |  |  |
Reblozyl | 234 |  |  | 172 |  |  | 440 |  |  | 328 |
Abecma | 132 |  |  | 89 |  |  | 279 |  |  | 156 |
Opdualag | 154 |  |  | 58 |  |  | 271 |  |  | 64 |
Zeposia | 100 |  |  | 66 |  |  | 178 |  |  | 102 |
Breyanzi | 100 |  |  | 39 |  |  | 171 |  |  | 83 |
Onureg | 44 |  |  | 32 |  |  | 78 |  |  | 55 |
Inrebic | 27 |  |  | 23 |  |  | 52 |  |  | 41 |
Camzyos | 46 |  |  | 3 |  |  | 75 |  |  | 3 |
Sotyktu | 25 |  |  | — |  |  | 41 |  |  | — |
Total New Product Portfolio | 862 |  |  | 482 |  |  | 1,585 |  |  | 832 |
Total In-Line Products and New Product Portfolio | 9,500 |  |  | 9,145 |  |  | 18,848 |  |  | 17,782 |
Recent LOE Products(a) |  |  |  |  |  |  |
Revlimid | 1,468 |  |  | 2,501 |  |  | 3,218 |  |  | 5,298 |
Abraxane | 258 |  |  | 241 |  |  | 497 |  |  | 455 |
Total Recent LOE Products | 1,726 |  |  | 2,742 |  |  | 3,715 |  |  | 5,753 |
Total revenues | $ | 11,226 |  |  | $ | 11,887 |  |  | $ | 22,563 |  |  | $ | 23,535 |
United States | $ | 7,891 |  |  | $ | 8,268 |  |  | $ | 15,924 |  |  | $ | 15,962 |
International | 3,160 |  |  | 3,427 |  |  | 6,309 |  |  | 7,154 |
Other(b) | 175 |  |  | 192 |  |  | 330 |  |  | 419 |
Total revenues | $ | 11,226 |  |  | $ | 11,887 |  |  | $ | 22,563 |  |  | $ | 23,535 |
(a) Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity. (b) Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations. Revenue recognized from performance obligations satisfied in prior periods was $75 million and $241 million for the three and six months ended June 30, 2023 and $184 million and $331 million for the three and six months ended June 30, 2022, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration